Patients who receive treatment with immune checkpoint inhibitors for advanced renal cell carcinoma and urothelial carcinoma are more likely to experience disease progression and death if they have liver metastases, a study found.
The approval was based on data from the randomized, open-label phase 3 CheckMate-9ER.
Patterns of disease spread varied significantly among patients with clear cell, papillary, and chromophobe renal cell carcinoma and may reflect differences in disease biology, according to investigators.
Increased risks persist beyond 6 months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i.
Two subtypes of papillary RCC – type I and type II – have been previously described.
Management of T3a renal cell carcinoma should not be based on anatomic features alone, but also take tumor size into account, according to investigators.
Arterial spin labeled (ASL) perfusion magnetic resonance imaging (MRI) is a non–contrast-based, noninvasive imaging modality that quantifies blood flow to tissue.
A phase 3 randomized active-controlled trial will evaluate atezolizumab plus cabozantinib among patients with advanced RCC whose disease progressed with ICIs.
Patients who were Black, had higher incomes, or who had undergone surgery were less likely to receive palliative care.
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
